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Abstract
Background: Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) Class I molecules bind
to peptide fragments of proteins degraded inside the cell and display them on the cell surface. We are interested in
peptide-HLA complexes involving peptides that are derived from proteins specifically expressed in cancer cells. Such
complexes have been shown to provide an effective means of precisely targeting cancer cells by engineered T-cells
and antibodies, which would be an improvement over current chemotherapeutic agents that indiscriminately kill
proliferating cells. An important concern with the targeting of peptide-HLA complexes is off-target toxicity that could
occur due to the presence of complexes similar to the target complex in cells from essential, normal tissues.
Results: We developed a novel computational strategy for identifying potential peptide-HLA cancer targets and
evaluating the likelihood of off-target toxicity associated with these targets. Our strategy combines sequence-based
and structure-based approaches in a unique way to predict potential off-targets. The focus of our work is on the
complexes involving the most frequent HLA class I allele HLA-A*02:01. Using our strategy, we predicted the off-target
toxicity observed in past clinical trials. We employed it to perform a first-ever comprehensive exploration of the
human peptidome to identify cancer-specific targets utilizing gene expression data from TCGA (The Cancer Genome
Atlas) and GTEx (Gene Tissue Expression), and structural data from PDB (Protein Data Bank). We have thus identified a
list of 627 peptide-HLA complexes across various TCGA cancer types.
Conclusion: Peptide-HLA complexes identified using our novel strategy could enable discovery of cancer-specific
targets for engineered T-cells or antibody based therapy with minimal off-target toxicity.
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Background
Peptide-HLA (Human Leukocyte Antigen) class I com-
plexes displayed on the cell surface play an important
role in the T-cell mediated immune response [1, 2]. The
approximately 9-residue long peptides originate from pro-
teins that are digested by the proteasome inside the cell
[3, 4]. Depending on whether the T-cell receptor recog-
nizes a peptide as self or non-self, an immune response
may be initiated [5]. Peptide-HLA complexes displayed
specifically on the surface of cancer cells provide an excel-
lent opportunity to develop targeted cancer therapeutics
[6]. Such therapeutics could include engineered T-cells
or “TCR-like” antibodies [7]. To inhibit the unwanted
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proliferation of cancer cells, the engineered T-cells are
designed to express a receptor that can bind to peptide-
HLA complexes on the surface of the cancer cells, thereby
effecting cytotoxicity [8–11]. “TCR-like” antibodies may
also be designed to link peptide-HLA complexes on can-
cer cells to cytotoxic T-cells [12–15]. Although these ther-
apeutic technologies are under constant development,
several studies have shown that they are very effective
in killing cells [8, 16–18]. Extreme caution is, therefore,
required to develop these therapeutic molecules so that
they specifically kill only cancer cells and not cells from
essential, normal tissues (a tissue that cannot be sacrificed
in the course of cancer therapy is considered essential).
For precisely killing the cancer cells using the engi-
neered T-cells or antibodies, it is important to target
peptide-HLA complexes that are present “only” on the
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surface of cancer cells [19, 20]. The presence of the tar-
get complexes on the surface of cells in essential, normal
tissues could easily result in adverse events [17, 21–23]. If
the target peptides, i.e., peptides in the target complexes,
are derived from genes that have low or no expression in
the essential, normal tissues, then the obvious implication
is that the adverse events due to toxic cross-reactivity can
be avoided. However, recent research has demonstrated
that avoiding the toxic cross-reactivity involving peptide-
HLA targets is not that straightforward, and therefore,
extremely challenging [24, 25].
Several clinical trials involving engineered T-cells tar-
geted against peptide-HLA complexes recently have
reported fatal adverse events. In one clinical trial [17],
9 cancer patients received engineered T-cells targeting
a peptide-HLA complex involving peptide KVAELVHFL
fromMAGEA3 and HLA-A*02:01. Melanoma antigen A3
or MAGEA3 is a cancer testis antigen, expressed in tumor
tissue and not significantly expressed in essential, normal
tissues. Therefore, targeting of peptides from MAGEA3
andmany other genes in theMAGE family was considered
unlikely to result in off-target toxicity. However, begin-
ning 1-2 days post infusion, 3 patients experienced mental
status changes, and 2 out of 3 patients lapsed into coma
and subsequently died. It was later discovered that the
fatal toxicity most likely occurred due to off-target effects
involvingMAGEA12 (amelanoma antigen gene expressed
in brain) peptide KMAELVHFL, which also binds to HLA-
A*02:01. In another clinical trial [23], two melanoma
patients, who received engineered T-cells designed to
bind to a MAGEA3 peptide (amino acid sequence EVD-
PIGHLY) in complex with HLA-A01:01 suffered fatal car-
diac toxicity. Subsequent to the fatal adverse events, it was
discovered that a peptide-HLA complex (ESDPIVAQY-
HLA-A*01:01) similar to the target complex was the most
likely culprit of off-target toxicity. The peptide is con-
tained in a gene called Titin (TTN) that is highly expressed
in heart and skeletal muscle.
The outcome from these two clinical trials suggests that
extreme caution is required when targeting peptide-HLA
complexes. As suggested by the investigations performed
after the clinical trials described above, a peptide that has
between 5 and 8 identical amino acids can potentially
cause off-target effects. Therefore, there are two criti-
cal factors when considering targeting of HLA-peptide
complexes. First, expression of the peptide in the target
complex should be cancer-specific. Second, peptides that
may form a cross-reacting complex (i.e., containing a pep-
tide similar to that of the target) should not be present
in essential, normal tissues. Attempts to predict cross-
reacting “off-targets” generally include a BLAST search
of the human peptidome to find sequences similar to the
target peptide, followed by selection of the most simi-
lar peptides predicted to bind the HLA allele of interest
that are ubiquitously expressed [22, 23]. The recently pub-
lished Expitope webserver is designed to perform these
steps in a systematic fashion [26]. The webserver com-
bines BLAST searches (to identify similar peptides), and
various prediction tools that predict whether the sim-
ilar peptides will form complexes with the HLA allele
of interest. The webserver also returns expression lev-
els of the peptide in cancer cell lines and normal tissues
from IlluminaHuman BodyMap (ArrayExpress accession:
E-MTAB-513; ENA archive: ERP000546).
In contrast to the scope of the Expitope webserver,
our work focuses on the identification of cancer-specific
peptide-HLA targets using gene expression data from
cancer tissues and essential, normal tissues. Here we
describe a novel computational strategy that analyzes the
canonical human peptidome, identifies potential peptide-
HLA cancer targets, and then prioritizes them based on
the likelihood of cross-reactivity that could be associated
with them. First, all possible 9-mer peptides in the canon-
ical human proteome that can bind the HLA-A*02:01
allele are identified. The current focus on HLA-A*02:01
allele is due to its high allelic frequency [27], the high
accuracy of binding prediction method for complexes
involving HLA-A*02:01 [28–31], and availability of crys-
tal structures of complexes between peptide-HLAs and
T-cell receptors/TCR-like antibodies. Based on the gene
expression data from the TCGA (The Cancer Genome
Atlas) cancer samples and adjacent normal tissue samples,
and the normal tissue samples from GTEx (Gene Tissue
Expression database) [32], cancer-specific peptide-HLA
complexes are identified. For each target complex, similar
complexes are identified using a combination of sequence
similarity and molecular modeling approaches in contrast
to just using a sequence similarity based approach as in the
case of Expitope webserver [26]. The similar complexes
that are expressed in essential, normal tissue samples from
the TCGA and GTEx databases are considered potential
off-targets. Target complexes are then prioritized based
on the number of predicted off-targets associated with
them; a target with lower number of off-targets associated
with it is assigned higher priority. Due to the computa-
tional nature of our work, instead of discarding targets
based on cross-reactivity predictions, we use predictions
to only prioritize targets for future cell-based validation
assays.
In the following section, we describe in detail our strat-
egy for identifying cancer-specific peptide-HLA targets,
derived from the canonical human proteome, across var-
ious cancer types. This description is followed by results
obtained from a comprehensive exploration of the human
proteome as well as some specific examples that demon-
strate the effectiveness of our approach towards discover-
ing peptide-HLA targets. We conclude with a discussion
of the strengths and weaknesses of our strategy in its
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current form, and possible directions for further improve-
ment.
Methods
We have developed a computational strategy to identify
potential cancer-specific peptide-HLA targets and prior-
itize these targets based on the likelihood of potential
cross-reactivity. Our strategy involves four steps: 1) 9-
mers are identified from each protein sequence in the
human proteome. 2) Binding affinities of the peptides
in complex with the HLA-A*02:01 (most frequent HLA
allele [27]) are computed and based on the predicted affin-
ity values, potential peptide-HLA complexes are selected.
3) Cancer-specific peptide-HLA complexes are identified
based on the expression of the peptide in cancer versus
essential, normal tissue samples. 4) For each of the pep-
tides in the potential cancer-specific complexes, similar
peptides in the human proteome are identified and their
degree of similarity (DoS) is calculated. The complexes are
then prioritized based on the number of similar complexes
at different DoS threshold levels. In the subsections below,
we describe the individual components of our strategy in
more detail.
Step 1: Extract human proteome
All human proteins and their canonical amino acid
sequences are extracted from the reviewed subset of the
UniProtKB database [33] (version September 2014). The
reviewed subset contains several proteins that correspond
to multiple alleles of HLA genes HLA-A, HLA-B, HLA-C,
and HLA-DRB1. The proteins that correspond to alleles
with highest allelic frequencies are kept as representa-
tive of the human proteome and the rest are removed.
The genes with highest allelic frequency in European Cau-
casian US population are HLA-A*02 (29.6%), HLA-B*07
(14.0%), HLA-C*07 (16.7%), and HLA-DRB1*15 (14.4%)
[27]. The reviewed subset also contains entries that cor-
respond to long-intergenic-noncoding RNA (lincRNA)
genes [34]; such entries are ignored because lincRNAs are
not known to get translated to proteins. In total 20,041
proteins are thus extracted. Since we are interested in
identifying peptide-HLA complexes, we extract poten-
tial peptides from the set of 20,041 proteins. HLA class
I molecules are known to bind peptides that are usually
8 to 10 residue long, although peptides that are longer
have also been identified. Among the 2,585 linear epitopes
involving HLA-A*02:01 available in the IEDB database
[35] (as of February 2015), 1737 (67.2%) contain peptides
that are 9-residue long. In this work, therefore, we only
consider peptides that are 9-mers. All overlapping 9-mers
are extracted from the protein sequences corresponding
to the 20,041 proteins. After removing the 9-mers that
contain non-standard amino acids, a set of 11,118,076
peptides remains.
Step 2: Potential peptide-HLA complexes
Potential peptide-HLA complexes are identified using
a webserver called NetMHCstab (version 1.0) [31].
NetMHCstab webserver employs a neural network based
machine learning model to predict the binding affinity of
a peptide and HLA allele. The predicted binding affinity
(output as IC50 value in nanomolars) estimates how tightly
the peptide and the HLA molecule bind to each other. A
peptide is considered a strong binder to a HLA allele if
the IC50 value is smaller than 50 nanomolars (nM); it is
considered a weak binder if the IC50 value is smaller than
500 nM. In this work, a peptide and HLA allele is consid-
ered a putative complex if the peptide is predicted to bind
with an affinity less than 500 nM. The set of 11,118,076
peptides is evaluated for binding affinity with the HLA-
A*02:01 allele using the NetMHCstab webserver which
results in the identification of 338,452 (3.04%) potential
peptide-HLA complexes.
Step 3: Cancer-specific complexes
The precise targeting of cancer cells requires that poten-
tial peptide-HLA targets are specific to cancer cells [21].
Thus, to evaluate whether or not a peptide-HLA com-
plex can be used for the precise targeting of cancer cells,
gene expression data from cancer tissue mRNA samples
and essential, normal tissue mRNA samples is compared.
In this work any normal tissue that can be sacrificed in
the process of treating cancer is classified as non-essential,
e.g., tissues from male and female reproductive organs
(breast, cervix, fallopian tube, testis, uterus, and vagina).
The gene expression data for the cancer tissue samples is
derived from TCGA (The Cancer Genome Atlas) repos-
itory. The gene expression data for the essential, normal
tissues is derived from TCGA as well as GTEx (Genotype-
Tissue Expression project) repository [32]. Note that in
this work we use normal tissue data from two different
sources so that we can ascertain with high confidence the
expression levels of a gene in the normal tissues.
Raw data produced from the RNA-Seq analysis [36] of
mRNA samples done by TCGA and GTEx is available
from the respective data repositories. The data used in this
work corresponds to 7,840 TCGA cancer samples (across
27 cancer types), 497 TCGA adjacent normal samples
(across 15 essential tissue types), and 2,928 GTEx normal
samples (across 22 essential tissue types). The distribu-
tion of the samples is tabulated in Additional files 1 and 2.
Although the raw data has been processed by TCGA and
GTEx to produce gene expression values, we decided to
use a common data processing pipeline to exclude any
potential discrepancy due to different processing pipelines
used by TCGA and GTEx. The data processing pipeline,
implemented by Omicsoft [37], has processed the raw
RNA-Seq data to produce the gene expression values in
each sample, which are measured in Reads Per Kilobase
Dhanik et al. BMC Bioinformatics  (2016) 17:286 Page 4 of 14
Per Million (RPKM) [38].Using these expression values,
the 75-percentile RPKM value of each gene in each can-
cer type as well as the 75-percentile RPKM value of each
gene in each essential, normal tissue type is derived. It
has been estimated that depending on the total amount
of RNA in the cell, a single copy of a transcript is equiv-
alent to somewhere between 0.5 and 5.0 RPKM [39]. A
peptide-HLA complex is, therefore, classified as specific
to a cancer type if the 75-percentile RPKM value of the
gene (from which peptide is derived) in cancer samples is
greater than 5.0, and the maximum of the 75-percentile
RPKM across all normal tissue types is less than 0.5. The
usage of the above RPKM thresholds implies that, given
the 29.6% allelic frequency of HLA-A*02:01 [27], in 5%
or more cancer patients of a specific type, at least one
copy of the target is present in the cancer cells and zero
copies in the essential, normal cells. Thus, based on the
gene expression values, we restrict discovery of targets
to those genes that are highly expressed in cancer cells
and weakly expressed in essential, normal tissue cells.
Out of the 338,452 potential peptide-HLA complexes,
a list of 627 potential cancer-specific complexes is thus
obtained.
Step 4: Off-target complexes
Although we have carefully identified cancer-specific
complexes so far, a therapeutic agent targeted at a peptide-
HLA complex can have potential off-target effects if sim-
ilar peptide-HLA complexes are present on the surface
of cells from the essential, normal tissues [22, 23]. We
have described in the Introduction Section a case study
where the off-target toxicity was caused due to the pres-
ence of a similar complex in which the amino acids of
the peptides were identical at only 5 positions (equiv-
alent to 4 mismatches) [23]. To our knowledge, toxic
cross-reactivity due to peptides with more mismatches
has not been reported yet. Therefore, we assume in this
work, that two peptide-HLA complexes can be consid-
ered similar if the HLA alleles are the same and the
peptides have 5 or more identical residues at the same
positions.
For each of the 627 peptide-HLA complexes, a list
of similar peptides in the human proteome (a set of
11,118,076 9-mer peptides) along with the degree of sim-
ilarity (DoS) between each pair of similar peptides is
derived. The DoS between two peptides is defined as
the number of identical amino acids in peptides at iden-
tical positions, which is same as the hamming distance
between the sequence strings of the two peptides [40].
Since the focus of this work is on 9-mer peptides, a
maximum DoS value of 9 implies that two peptides are
identical. The lower the DoS, the lower the degree of sim-
ilarity and two peptides are considered dissimilar if DoS is
less than 5.
Not all of the similar complexes are however a cause
for concern with regard to potential toxicity. If the 95-
percentile expression of the similar peptide is greater than
0.5 in any essential, normal tissue type, then we consider
that the similar complex will likely result in toxic off-
target effects. We have utilized very conservative criteria
for determining toxicity so that the risk of not being able
to predict potential off-target toxicity is minimal. The tar-
get peptide-HLA complexes are prioritized on the basis
of the number of associated similar complexes that can
potentially result in toxic off-target effects. The higher the
number of such similar complexes, the more likely is a
toxic off-target effect.
One potential limitation of our approach is that the
number of similar complexes is overestimated, because
the amino acid positions in the peptides are not dis-
criminated with respect to their importance for bind-
ing a particular therapeutic TCR or TCR-like antibody.
Amino acid positions in a peptide that are involved
in hydrophobic contacts and/or hydrogen bonds with
the TCR/antibody are considered important for bind-
ing the therapeutic molecule, and the rest are consid-
ered non-important [41, 42]. Since this work focuses on
peptide-HLA complexes involving HLA-A*02:01, we took
advantage of the structures of complexes of peptide-HLA
and TCR/antibody in the Protein Data Bank (PDB) [43]
to determine the importance of each amino acid posi-
tion in the peptide, and then incorporated this into our
strategy.
There are 32 available crystal structures that involve a 9-
mer peptide (containing standard amino acids) with HLA-
A*02:01 in complex with a TCR/antibody (see Additional
file 3). For any other HLA allele, very few such struc-
tures are available. In each of the 32 crystal structures, the
important and non-important peptide positions are iden-
tified, thus producing a contact pattern corresponding to
the 9 positions in the peptide. The hydrophobic contacts
and hydrogen bond interactions are identified using soft-
ware called Chimera [44]. A peptide position is considered
to be in hydrophobic contact when the van der Waals
distance between any side chain atoms at that position
with any atom in the TCR/antibody is between 0.0Å and
0.4Å. Similarly a hydrogen bond is considered to exist
between a hydrogen atom connected to an electronegative
atom (donor) and another electronegative atom (acceptor)
when the distance between the donor and the acceptor
is less than 4Å and the angle donor-hydrogen-acceptor is
less than 30°. Out of the 32 contact patterns thus iden-
tified, only 21 are unique (see Additional file 4). Using
these 21 patterns, a simple predictor can classify a posi-
tion of a query peptide as non-important if fewer than a
threshold number of patterns show the position as impor-
tant. Clearly, the simple predictor is agnostic of the query
peptide sequence.
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We have developed an improved predictor based on
molecular modeling. Given a query peptide, structures of
peptide-HLA-A*02:01 complexes are modeled by mutat-
ing the amino acids of peptides in the 32 PDB struc-
tures to match the query peptide’s amino acid sequence.
After mutations are applied, structures are energy mini-
mized to eliminate steric clashes and the structure(s) with
any remaining clashes are discarded. Both mutations and
energyminimization are done using Chimera in its default
settings [44]. Contact patterns are then computed for
modeled structures of peptide-HLA-TCR/antibody com-
plexes involving the query peptide and unique patterns are
identified. Similar to the simple predictor, a peptide posi-
tion is classified as non-important if fewer than a thresh-
old number of patterns from the modeled structures show
the position as important.
We performed a leave-one-out validation experiment
[45] to ascertain the Receiver Operator Characteristics
(ROC) of the simple predictor and the modeling-based
predictor. Each predictor was used to identify non-
important peptide positions for known peptide-HLA-
TCR/antibody complex based on the remaining known
complexes. At different threshold values, the number
of true positives (position correctly predicted as non-
important), true negatives (position correctly predicted as
important), false positives (position incorrectly predicted
as non-important), and false negatives (position incor-
rectly predicted as non-important) were calculated, upon
which the true positive rate and false positive rate were
calculated. The ROC curves obtained for the simple and
modeling-based predictors are shown in Fig. 1. The Area
Under Curve (AUC) for the simple predictor is 0.80 and
for the modeling-based predictor is 0.90. More impor-
tantly, at threshold value equal to 2, the true positive rate is
0.68 and the false positive rate is 0 for the modeling-based
predictor.
Clearly, we cannot identify all non-important positions
in a peptide, but the ones we identify are the correct
ones, at least based on the limited structure data we have
so far in PDB. We may still overestimate the importance
of certain peptide positions but it allows us to err on
the side of caution when predicting similar complexes
that can result in potentially toxic off-target effects. In
general at least 3 peptide positions are considered to
play a role in TCR binding [46], therefore similar com-
plexes with similarity at fewer than 3 important positions
are discarded. The peptide-HLA complexes are thus re-




From UniProtKB database [33], we extracted 20,108
canonical protein sequences that represent the human
proteome. The 11,118,076 9-mer peptides derived from
the protein sequences were input into the NetMHCstab
webserver to compute the binding affinity of each pep-
tide with HLA-A*02:01 [31]. The distribution of the IC50
values of the peptides is shown in Additional file 5. As
illustrated in the top panel of the figure, 338,452 peptides
were predicted to bind HLA-A*02:01 with IC50 less than
500 nM. The distribution of the IC50 values of the 338,452
peptides is shown in more detail in the bottom panel of
the figure. As illustrated, 104,764 peptides were predicted
to bind HLA-A*02:01 with IC50 less than 50 nMwhich is a
criterion used to classify a peptide as a strong binder. For
the purposes of identifying potential peptide-HLA tar-
gets, we further analyzed the cancer specificity of 338,452
and identified 627 potential cancer-specific peptide-HLA
targets across 18 TCGA cancer types.
The distribution of the number of targets specific to
each cancer type is listed in Table 1. The highest number
(72) of targets was identified for skin carcinoma (SKCM)
cancer type that is a focus area for the development
of therapeutic engineered T-cells [17, 47, 48]. None of
the identified targets are specific for tumor types ACC,
COAD, KIRC, KIRP, LUAD, PAAD, READ, SARC, and
THCA (see Additional file 1 for TCGA tumor type codes).
There are 359 unique targets as some of the targets are
associated with multiple cancer types. The peptides that
constitute the 627 potential targets were derived from 24
unique genes. The distribution of the number of peptides
(and unique peptides) derived from each gene is listed in
Table 2. Many MAGE (melanoma antigen) family genes
are the focus of therapeutic development programs [17,
22, 49] as they are primarily expressed in non-essential
testis tissue. Among the 24 genes from which our tar-
gets were derived, 8 MAGE genes are present. Since we
explored the full human proteome to identify potential
peptide-HLA targets, 24 genes have varied subcellular
localizations (intracellular, membrane, secreted, etc.). The
distribution of the number of targets with respect to the
cancer types and genes from which the peptides were
derived is listed in Table 3. Genes such as MAGEA3
and MAGEA6 contributed targets for 7 cancer types
each, while genes such as UMODL1, NLRP4, MAGEC2,
ANKRD30A, and GPRC6A contributed targets for only 1
cancer type.
Prioritized targets
The 627 potential targets were prioritized based on the
likelihood of off-target toxicity. The targets were first pri-
oritized by the increasing number of associated off-targets
at DoS greater than or equal to 6. Further prioritization
was similarly done based on similar complexes at DoS
greater than or equal to 5. If multiple targets had same
number of similar complexes, a target with higher expres-
sion in tumor was prioritized higher. As described in the
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Fig. 1 Receiver-operator characteristics of predictors that identify peptide positions which are not important for binding interactions with a
therapeutic molecule. A simple PDB-based predictor and a molecular modeling based predictor were compared
Methods section, we used a molecular modeling based
predictor to discriminate important and non-important
peptide positions. The prioritized 627 targets are listed
in Additional file 6. The number of predicted off-targets
associated with each of the 627 targets are shown in Fig. 2,
each panel in the figure shows the number of off-targets
Table 1 Distribution of peptide-HLA targets with respect to




















See Additional file 1 for the description of TCGA tumor types
based on different combinations of usage of molecular
modeling based predictor and DoS threshold levels. The
figures show that after using the modeling-based predic-
tor, there are fewer off-targets associated with the 627
targets at both DoS ≥ 5 and DoS ≥ 6 threshold lev-
els. Fewer than 100 off-targets are associated with 317
and 624 targets at DoS ≥ 5 and DoS ≥ 6 respectively
(right panels in Fig. 2). Out of the 317 and 624 targets,
198 and 614 targets respectively have fewer than 50 off-
targets associated with them. Thus, even though there are
a few targets with a large number (> 1000) of off-targets
associated with them, there are a significant number of
targets with reasonable number of associated off-targets
that could be experimentally evaluated for cross-reactivity
in a tractable manner. It is worth noting that at DoS ≥
5, there is only 1 target without any associated potential
off-target, thus demonstrating the challenge involved in
minimizing potential toxic cross-reactivity that could be
associated with peptide-HLA targets.
The top-20 peptides that in complex with HLA-A*02:01
allele form the top-20 cancer-specific peptide-HLA tar-
gets are listed in Table 4. Each target is listed along with
the tumor type for which the target was identified, the
gene from which the target peptide was derived, the pre-
dicted binding affinity, the 75-percentile expression of
the peptide (gene) in the tumor samples corresponding
to the tumor type, and the number of predicted off-
targets at different DoS threshold levels that can poten-
tially cause toxicity. All of the top-20 targets do not have
any associated off-targets at DoS ≥ 6, and have 18 or
fewer off-targets at DoS ≥ 5. The 20 targets were iden-
tified for 7 tumor types: DLBC, GBM, LAML, LGG,
LIHC, LUSC, and SKCM. Peptides from MAGE family
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Table 2 Distribution of peptide-HLA targets with respect to the
genes from which the peptides are derived. The number of
unique peptide-HLA targets derived from each gene is also listed
Gene Count Unq.count
1 MAGEA3 84 12
2 MAGEA6 70 10
3 UMODL1 54 54
4 MAGEA9B 52 13
5 NLRP4 47 47
6 MAGEA4 45 9
7 CNTNAP5 35 35
8 MAGEA12 32 16
9 RPE65 30 15
10 ANKRD30A 23 23
11 SMC1B 22 22
12 MAGEA1 22 11
13 MAGEC2 18 18
14 DNTT 16 16
15 TGM4 16 16
16 MAGEA11 13 13
17 TRIM51 11 11
18 DSCR8 10 5
19 EPYC 8 8
20 POTEM 7 7
21 COX7B2 5 5
22 C7orf72 4 4
23 MTRNR2L1 2 2
24 KLKP1 1 1
Some genes provided targets that are specific to multiple cancer types, e.g.,
MAGEA3 provided 12 unique targets that are specific to 7 different cancer types,
equivalent to 84 targets, in total, across 7 cancer types
genes feature in the top-20 targets list, but the genes are
MAGEC2 and MAGEA11 instead of MAGEA3 that has
been the focus of most of the research and clinical work
on peptide-HLA targets. Perhaps the eluding success with
MAGEA3-derived targets is due to the potential cross-
reactivity associated with these targets. Although the 12
peptides derived from MAGEA3, which are in the list
of 627 targets, include well-investigated peptides such as
FLWGPRALV and KVAELVHFL [50], the highest ranked
(36th) peptide is GNWQYFFPV.
Top targets for 3 different cancer types
The top targets were identified for Diffuse Large B-Cell
Lymphoma (DLBC), Acute Myeloid Leukemia (LAML),
and Skin cutaneous melanoma (SKCM) cancer. These
targets are peptides HLSPIDCEV (ranked 1st), LTSMWS-
PAV (ranked 2nd), and SLSVMSSNV (ranked 4th) respec-
tively. Following are the three genes from which the
Table 3 Distribution of targets with respect to the cancer type
and genes from which the peptides are derived
Tumor Gene Count
1 BLCA MAGEA12 16
2 BLCA MAGEA9B 13
3 BLCA MAGEA3 12
4 BLCA MAGEA6 10
5 BLCA MAGEA4 9
6 BRCA ANKRD30A 23
7 CESC SMC1B 22
8 DLBC NLRP4 47
9 DLBC MAGEA9B 13
10 DLBC C7orf72 4
11 ESCA MAGEA3 12
12 ESCA MAGEA6 10
13 ESCA MAGEA4 9
14 GBM RPE65 15
15 HNSC MAGEA3 12
16 HNSC MAGEA6 10
17 HNSC MAGEA4 9
18 KICH CNTNAP5 35
19 LAML UMODL1 54
20 LAML DNTT 16
21 LGG RPE65 15
22 LIHC MAGEA3 12
23 LIHC MAGEA1 11
24 LIHC MAGEA6 10
25 LIHC COX7B2 5
26 LUSC MAGEA9B 13
27 LUSC MAGEA11 13
28 LUSC MAGEA3 12
29 LUSC MAGEA1 11
30 LUSC MAGEA6 10
31 LUSC MAGEA4 9
32 OV EPYC 8
33 PRAD TGM4 16
34 PRAD POTEM 7
35 PRAD KLKP1 1
36 SKCM MAGEC2 18
37 SKCM MAGEA12 16
38 SKCM MAGEA3 12
39 SKCM TRIM51 11
40 SKCM MAGEA6 10
41 SKCM DSCR8 5
42 STAD MAGEA3 12
43 STAD MAGEA6 10
44 UCEC MTRNR2L1 2
45 UCS MAGEA9B 13
46 UCS MAGEA4 9
47 UCS DSCR8 5
See Additional file 1 for the description of TCGA tumor types
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Fig. 2 Number of predicted off-targets for each potential peptide-HLA target. The four panels show the number of off-targets predicted based on
different DoS threshold levels and based on the usage of the molecular modeling based predictor to identify non-important and important peptide
positions. In each panel, the targets are sorted by decreasing y-axis value
peptides were derived: NLRP4 (NACHT, LRR and PYD
domains-containing protein 4), UMODL1 (Uromodulin-
like 1), and MAGEC2 (Melanoma-associated antigen C2).
Expression of the peptides (genes) in each GTEx nor-
mal sample, TCGA normal sample, and tumor samples
Table 4 Top 20 peptide-HLA targets prioritized by the number
of associated off-targets
Tumor Peptide Gene IC50 RPKM.tumor Sim.5 Sim.6
1 DLBC HLSPIDCEV NLRP4 42.48 6.57 0 0
2 LAML LTSMWSPAV UMODL1 279.13 6.47 1 0
3 DLBC HLDHPHPAV NLRP4 147.43 6.57 2 0
4 SKCM SLSVMSSNV MAGEC2 265.87 19.91 3 0
5 DLBC MMAWSDNKI NLRP4 90.11 6.57 3 0
6 LIHC TQIGIEWNL COX7B2 229.74 19.13 4 0
7 DLBC CLFEMQDPA NLRP4 37.51 6.57 5 0
8 LAML YLSHPSCNV UMODL1 16.04 6.47 5 0
9 LIHC GIEWNLSPV COX7B2 361.90 19.13 7 0
10 LUSC GLGCSPASI MAGEA11 471.75 10.52 7 0
11 LGG RQAFEFPQI RPE65 456.69 6.60 7 0
12 GBM RQAFEFPQI RPE65 456.69 6.30 7 0
13 DLBC GMWTDTFEF NLRP4 172.47 6.57 10 0
14 SKCM YLNWQDTAV TRIM51 10.30 7.35 11 0
15 LUSC VLWGPITQI MAGEA11 24.07 10.52 15 0
16 DLBC TLDHTGVVV NLRP4 497.98 6.57 15 0
17 LGG TMGVWLHIA RPE65 314.41 6.60 16 0
18 GBM TMGVWLHIA RPE65 314.41 6.30 16 0
19 SKCM KVWVQGHYL MAGEC2 407.64 19.91 18 0
20 LAML KINCNNFRL UMODL1 304.37 6.47 18 0
The table lists the peptides which in complex with HLA-A*02:01 form the targets,
the cancer types which specifically express the targets, the genes from which the
peptide were derived, the predicted binding affinities (IC50 in nanomolars) of the
target complexes, the 75% expression (in RPKM) of genes in the tumor samples,
and the number of potential off-targets at DoS ≥ 5 (Sim.5) and DoS ≥ 6 (Sim.6). See
Additional file 1 for the description of TCGA tumor types
(from the tumor type associated with the targets) is shown
in Fig. 3. As illustrated, expression of the peptides in
normal samples is very low compared to the expression
in the tumor samples. Through structural modeling based
analysis of contact patterns, positions {1,5,7}, {1,4,5},
and {4,5,8} were classified as important for the pep-
tides HLSPIDCEV, LTSMWSPAV, and SLSVMSSVNV
respectively.
The predicted off-targets associated with two of the
three targets (HLSPIDCEV has no predicted associated
off-target) are listed in Table 5. The table lists peptides
that are similar to the target peptide, binding affinities
of the similar peptides to HLA-A*02:01, genes from
which the similar peptides were derived, and top 2 nor-
mal tissue samples each from GTEx and TCGA that
express these genes at a level which could result in toxic
cross-reactivity. The peptide LTSMWSPAV (DLBC tar-
get) has 1 associated off-target that was derived from
the gene DNAH7 (Dynein heavy chain 7, axonemal).
The expression levels of DNAH7 in essential, normal
tissue samples in GTEx and TCGA databases suggest
potential concern for toxic cross-reactivity in brain, lung,
and other tissues. The peptide SLSVMSSNV (SKCM tar-
get) has 3 associated off-targets that were derived from
the genes SLC31A2 (Solute carrier family 31, mem-
ber 2), OTOP2 (Otopetrin 2), and OTOP3 (Otopetrin
2). The expression levels of these genes in essential,
normal tissue samples suggest potential concern for
toxic cross-reactivity in small intestine, colon, and other
tissues.
MAGEA3 peptide KVAELVHFL
Fatal adverse events were reported in the clinical trial
involving engineered T-cell based therapy against the
MAGEA3 peptide KVAELVHFL-HLA-A*02:01 complex
Dhanik et al. BMC Bioinformatics  (2016) 17:286 Page 9 of 14
Fig. 3 Cancer and essential, normal tissue expression of the top target peptides for three different cancer types. Each dot represents the RPKM value
of the peptide/gene in one sample. The essential, normal tissue samples are shown in black color and the cancer samples are shown in magenta
color. See Additional file 1 for the description of TCGA tumor types
[17]. Subsequently, 9 different peptides very similar to
the target peptide were experimentally evaluated as
potential off-targets and peptide KMAELVHFL from the
gene MAGEA12 was implicated as the most likely off-
target. Using our strategy, we identified 6 (including the
MAGEA12 peptide) out of the 9 peptides as potential off-
targets that are listed in Table 6. Peptide KVVSLVHFL
from MAGEB18 was not identified because expression
of MAGEB18 in essential, normal tissues is too low for
the peptide to be recognized as an off-target by our
Table 5 Predicted off-targets associated with top LAML and SKCM specific targets
Tumor Target Target.gene Off.target IC50 Gene Normal.tissue.samples
1 LAML LTSMWSPAV UMODL1 LLKMWFPEV 21.60 DNAH7 Pituitary, Brain, LUAD, LUSC
2 SKCM SLSVMSSNV MAGEC2 MLAVMSYNT 206.18 SLC31A2 Blood, Salivary Gland, HNSC, LUAD
MLYVMWKNV 137.41 OTOP2 Colon, S. Intestine, COAD, READ
VLFVMWKNV 276.13 OTOP3 Esophagus, S. Intestine, STAD, HNSC
The table lists the off-target peptides, binding affinity (IC50 in nanomolars) of peptide-HLA-A*02:01 complexes involving the off-target peptides, genes from which the
off-target peptides were derived, and the essential, normal tissue types from GTEx and TCGA with high expression of the off-target peptides/genes. See Additional file 1 for
description of TCGA tumor types
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Table 6 Predicted off-targets associated with target KVAELVHFL-HLA-A*02:01 derived from MAGEA3
Off.target DoS IC50 Off.target.gene Normal.tissue.samples
1 KVAELVHIL 8 103.72 DDX28 Muscle, Skin, BLCA, HNSC
2 KVAELVQFL 8 46.07 MAGEC3 Brain, Spleen, THCA, ESCA
3 KMAELVHFL 8 2.66 MAGEA12 Brain, Muscle, BLCA, HNSC
4 SAAELVHFL 7 187.05 EPS8L2 Esophagus, Kidney, HNSC, STAD
5 KLEELVHFL 7 11.98 MRVI1 Blood Vessel, Blood, ESCA, STAD
6 SAADLVHFL 6 211.83 EPS8 Blood Vessel, Adipose Tissue, COAD, READ
The table lists the off-target peptides, degree of similarity of the off-target peptides with the target peptide, binding affinity (IC50 in nanomolars) of peptide-HLA-A*02:01
complexes involving the off-target peptides, genes from which the off-target peptides were derived, and the essential, normal tissue types from GTEx and TCGA with high
expression of the off-target peptides/genes
strategy. The other two peptides that were not identified
are GIAELVHFS (from gene PPP2R1B) and TVAELVQFV
(from gene MAGEF1). These two peptides are not con-
tained in the canonical human proteome sequences
derived from UniProtKB and were therefore not identi-
fied. Although we identified KVAELVHFL as a potential
SKCM target, it was found to be associated with 273, 30,
12, and 5 potential off-targets at DoS ≥ 5, 6, 7, and 8
respectively. Therefore, it was ranked 516th out of the 627
potential targets making it a very low-priority target.
CTAG1A/NY-ESO-1 peptide SLLMWITQC
The cancer testis antigen 1 A (CTAG1A, also known as
CTAG1B/NY-ESO-1) peptide SLLMWITQC in complex
with HLA-A*02:01 is an active target for engineered T-
cell based therapy in multiple myeloma, synovial sarcoma,
and advanced melanoma [51]. In phase I/II clinical trials,
the safety of the therapy targeting the CTAG1A peptide
has been demonstrated [52]. This target was not in our
list of 627 targets because the 75-percentile expression
of CTAG1A/CTAG1B in the cancer samples from each
TCGA cancer type is less than 5 RPKM (we recognized
a peptide as a target for a particular cancer type if the
75-percentile expression of the peptide/gene was greater
than 5 RPKM). As described earlier, our aim with using
the 75-percentile expression values was to identify targets
that could be present in at least 5% of the TCGA cancer
patients of a specific type. But even if our comprehen-
sive analysis of the human proteome might miss targets
that can exist in a smaller subset of cancer patients, our
strategy could still be used to predict the likelihood of
cross-reactivity associated with any peptide-HLA target.
Fortunately, multiple structures of this particular target in
complex with TCR are available in the Protein Data Bank.
These structures inform that peptide positions 4, 5, 6, 7,
and 8 are important for TCR binding. Incorporating this
information into our strategy, we identified 18 off-targets
at DoS ≥ 5 and 1 off-target at DoS ≥ 6 that are listed in
Table 7. If peptide SLLMWITQC were a part of our target
list, it would have been ranked 51st from the top. The high
ranking of the target due to fewer predicted off-targets
thus demonstrates the ability of our strategy to correctly
prioritize a target that has not been associated with any
toxic off-target effects in clinical trials to date.
Discussion
In this paper, we have described a novel computational
strategy to identify potential cancer-specific peptide-HLA
complexes that can be targeted by therapeutics such as
engineered T-cells and “TCR-like” antibodies [8, 8–11,
16–18]. The strength of our strategy lies in not only iden-
tifying peptide-HLA targets but also in estimating the
potential toxic cross-reactivity that could result from ther-
apeutic action against such targets. After a comprehensive
analysis of the canonical human proteome, we identified
627 peptide-HLA-A*02:01 targets that are specific to 18
different TCGA cancer types. Only those peptides that are
highly expressed in cancer samples, and have extremely
low expression in essential, normal tissue samples were
considered potential targets. Peptides similar to the target
peptide were identified from the human proteome based
on the similarity of residues. We introduced a molecu-
lar modeling-based predictor that classifies peptide posi-
tions as important or non-important for interacting with
potential therapeutic molecules, and used the predictor to
better estimate peptide similarity. The targets were pri-
oritized based on the number of peptides in the human
proteome that are similar to the target peptides and are
also expressed in essential, normal tissue samples.
At different levels of peptide similarity, measured as the
degree of similarity (DoS) value, each target peptide is
associated with a different number of potential off-targets
(similar peptides). The higher the DoS value, the fewer is
the number of similar peptides. The list of Top-20 prior-
itized target peptides (see Table 4) shows that although
at DoS ≥ 6 threshold level, there is no associated off-
target, at DoS≥ 5 there are more than 1 off-targets except
in the case of the topmost target. We earlier discussed
an off-target peptide ESDPIVAQY from Titin (TTN) that
was implicated in fatal cardiac toxicity [22]. The DoS of
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Table 7 Predicted off-targets associated with target SLLMWITQC-HLA-A*02:01 derived from CTAG1A/NY-ESO-1
Off.target DoS IC50 Off.target.gene Normal.tissue.samples
1 WLLPWICQC 6 66.56 GRID1 Brain, Thyroid, THCA, STAD
2 SLVKPITQL 5 206.18 ITGAM Blood, Spleen, LUAD, LUSC
3 QLLMGIEQA 5 492.62 CABIN1 Blood, Blood Vessel, THCA, STAD
4 FLLHWITRG 5 335.50 NPC1L1 Liver, Small Intestine, STAD, LIHC
5 SILMYITSL 5 67.65 DMD Muscle, Nerve, BLCA, STAD
6 PLLYNITQV 5 321.29 PHTF2 Muscle, Blood, HNSC, BLCA
7 TLLMVITGV 5 13.86 KIRREL2 Pancreas, Stomach, KIRP, KICH
8 LLTMHITQL 5 133.75 FBXL22 Colon, Blood Vessel, BLCA, STAD
9 FLLMFIKQL 5 37.51 LRBA Pituitary, Skin, KIRC, KICH
10 MLLMKIQQL 5 62.71 SIMC1 Adrenal Gland, Muscle, ESCA, STAD
11 SLVYPITQV 5 30.87 BNC1 Salivary Gland, Esophagus, HNSC, STAD
12 RLLQVITQT 5 236.04 DNAH1 Blood, Liver, ESCA, LUAD
13 GLLNWITGA 5 13.06 VWA5B1 Pituitary, Bladder, KIRP, KIRC
14 SLSMGITLI 5 72.18 SLC16A14 Brain, Spleen, HNSC, LIHC
15 SALDQITQV 5 423.37 DNAH2 Lung, Brain, LUAD, LUSC
16 SILVWIFQA 5 52.18 SYNGR4 Brain, Pancreas, STAD, COAD
17 SLSKKITQV 5 59.73 CCDC38 Liver, Spleen, LIHC, HNSC
18 FLNRWITFC 5 52.74 IL2 Bladder, Small Intestine, STAD, BLCA
The table lists the off-target peptides, degree of similarity of the off-target peptides with the target peptide, binding affinity (IC50 in nanomolars) of peptide-HLA-A*02:01
complexes involving the off-target peptides, genes from which the off-target peptides were derived, and the essential, normal tissue types from GTEx and TCGA with high
expression of the off-target peptides/genes
the target and the off-target peptide is 5, which informs
us that a peptide that is similar at 5 identical amino acid
positions cannot be disregarded as a potential off-target.
Therefore, our finding that almost all the potential tar-
gets could have off-targets at DoS ≥ 5 emphasizes the
challenge involved in developing therapeutics targeting
peptide-HLA complexes.
Given the challenges involved, our comprehensive anal-
ysis of the canonical human proteome for identifying
novel cancer-specific peptide-HLA targets prioritized by
likelihood of toxic cross-reactivity, could prove to be
an important step in the development of therapeutic
molecules with low cross-reactivity. We have demon-
strated the ability to predict the potential toxic cross-
reactivity that was observed in the clinical trial involving
administration of engineered T-cells targeting MAGEA3
peptide KVAELVHFL in complex with HLA-A*02:01 [17].
Based on our analysis, this MAGEA3 peptide may not
have been investigated in a clinical trial.
The current work is focused on targets that involve
peptides in complex with HLA-A*02:01. This gives us
two benefits: 1) the binding affinity predictions are most
accurate for the complexes involving HLA-A*02:01 [29,
31], and 2) the availability of crystal structures of the
complexes involving HLA-A*02:01 allows us to accurately
identify the peptide positions that are important or not
important for the binding interactions with a T-cell recep-
tor (TCR) or antibody. To predict potential off-targets, we
identify peptides in the human proteome that are simi-
lar to a target peptide, two peptides are more similar if
they have more amino acids identical in identical peptide
positions. The identification of non-important positions
allows us to ignore a peptide as a candidate off-target if
it is mostly similar at positions that are not important
for the binding interactions with TCR or antibody. Thus,
we avoid overestimating the number of the off-target
peptides to some extent.
Although the strategy described here is focused on
HLA-A*02:01, it can be used to predict cross-reactivity
of complexes involving any other HLA allele if binding
affinities of complexes can be estimated. We slightly mod-
ified our strategy to make cross-reactivity predictions for
the MAGEA3 peptide EVDPIGHLY-HLA-A*01:01 com-
plex [22]. In the Step 2 of our strategy, NetMHCstab
webserver was used to predict binding affinities for all 9-
mer peptides (from the human proteome) in complex with
HLA-A*01:01 instead of HLA-A*02:01 [31]. Since very
few crystal structures of peptide-HLA-A*01:01 complexes
are available, it was not possible to discriminate impor-
tant and not-important peptide positions. We identified
68 potential off-targets that are expressed in essential,
normal tissues and could result in off-target toxicity. Even
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though the number 68 could be an overestimate because
we were not able to discriminate the importance of pep-
tide positions, most importantly, the peptide ESDPIVAQY
from Titin (TTN) was identified as the off-target with the
highest expression in essential, normal tissues among the
68 potential off-targets.
There are some limitations to our strategy, several of
which could be addressed in future work. 1) It is limited
to 9-mer peptides and HLA-A*02:01, but can be easily
expanded in the future by taking advantage of the peptide-
HLA binding prediction algorithms that can handle pep-
tides of varied lengths and different HLA alleles. 2) It
employs computational predictions of peptide-HLA bind-
ing affinities, although we consider even a weakly binding
peptide (predicted IC50 < 500 nM) as a potential com-
plex, we could still miss some potential peptides that are
predicted to be non-binders, but actually are binders. 3) It
ignores two important components of the mechanism by
which a peptide gets presented at the cell surface by aHLA
molecule. Proteasomal cleavage and TAP (Transporter
associated with antigen processing)-peptide binding are
critical for peptide presentation along with peptide-HLA
binding [53]. There are a few computational algorithms
available that predict proteasomal cleavage likelihood of
a peptide [54] and TAP-peptide binding [55, 56], but
these algorithms are less accurate. However, development
of improved algorithms in the future would allow us to
incorporate them in our strategy. 4) It explores the full
canonical human proteome to identify targets and off-
targets, which means that any peptide that is part of gene
isoforms [57] or common allelic variations is ignored. Our
future work will address this issue by exploring the full
human proteome in more detail, however it needs to be
emphasized that even if we analyze the full proteome by
including every known isoform, a patient can have novel
isoforms of a protein (novel peptides) that have not been
discovered so far.
It needs to be emphasized that the targets and the
associated off-targets that we have discovered require
experimental validation which is beyond the scope of
our purely in-silico work. Given the computational lim-
itations described above, a subset of the targets and
associated off-targets may not be validated. That is pre-
cisely the reason we have not filtered out any poten-
tial target based on the cross-reactivity analysis. Instead
we have only used it to prioritize potential cancer-
specific targets and have purposefully erred on the side of
caution.
Conclusions
To date, a simple two-step strategy has been used to
discover cancer-specific peptide-HLA targets for engi-
neered T-cell or antibody therapy. Such a strategy
involves the discovery of cancer-specific genes in the
first step followed by the identification of the HLA
binding peptides in the next step. Virtually no attention
is given to the likelihood of toxic cross-reactivity which
has led to the focus on MAGEA3 and other cancer-
testes antigen genes that are not expressed in essen-
tial, normal human tissues. However, clinical trials
have shown the dangers involved in not considering
the potential off-targets in therapies involving peptide-
HLA targets. Our strategy provides a unique approach
to discovering cancer-specific peptide-HLA targets for
engineered T-cell or antibody therapy. The prioritized
target list derived from the comprehensive exploration
of the human peptidome presents a fresh starting point
for the systematic discovery of specific peptide-HLA
targets in various cancer types which will hopefully lead
to the development of therapies with minimal off-target
toxicity.
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